References
- SEER Cancer Stat Facts: chronic myeloid leukemia [Internet]. Bethesda (MD): National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html
- National Comprehensive Cancer Network Guidelines. Chronic myeloid leukemia. v.4. Fort Washington PA): National Comprehensive Cancer Network; 2018.
- Jabbour EJ, Hughes TP, Cortés JE, et al. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymph. 2014;55:1451–1462.
- Jain P, Kantarjian H, Alattar ML, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2:e118–e128.
- Kreys ED, Frei CR, Villarreal SM, et al. Evaluation of long-term chronic myeloid leukemia treatment practices with tyrosine kinase inhibitors in a national cohort of veterans. Pharmacotherapy. 2017;37:278–286.
- Brunner AM, Campigotto F, Sadrzadeh H, et al. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013;119:2620–2629.
- Goldberg SL, Chen L, Guerin A, et al. Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin. 2013;29:1075–1082.
- Haque R, Shi J, Chun J, et al. Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO. J Am Pharm Assoc. 2017;57:303–310.
- Guérin A, Chen L, Dea K, et al. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin. 2014;30:1345–1352.
- Guérin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ. 2014;17:89–98.
- Di Bella NJ, Bhowmik D, Bhor M, et al. The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. Clin Lymph Myeloma Leuk. 2015;15:599–605.
- Saleh MN, Haislip S, Sharpe J, et al. Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting. Curr Med Res Opin. 2014;30:529–536.
- Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, et al. Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency. JMCP. 2017;23:214–224.
- Goldberg SL, Cortes JE, Gambacorti-Passerini C, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017;92:1214–1223.
- Jabbour EJ, Lin J, Siegartel LR, et al. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ. 2017;20:1007–1012.
- Etienne G, Huguet F, Guerci-Bresler A, et al. Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study. Br J Haematol. 2016;174:71–80.